- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterSaturday, June 5, 2004
 |
 |
In order to print the required documentation, you will need Adobe Reader, which is available for free on the Adobe Website.
OncoLink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.
|
ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma. Final results of the IIL HD9601 randomized trial
Presenter: M. FedericoPresenter's Affiliation: Intergruppo Italiano LinfomiType of Session: ScientificBackground The standard treatment for advanced Hodgkin's lymphoma (HL) is ABVD chemotherapy 30% of patients with advanced HL do not respond to... |
|
|
Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer.
Presenter: M.R. SmithPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Several small retrospective studies have reported that GnRH agonists increase fracture risk in prostate patients. However, the... |
|
|
Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
The cDNA arrays and Gene Chips discussed in this study have not been approved by the FDA for use in patients. Presenter: Lajos PusztaiPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Gene... |
|
|
Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? (EORTC 22911)
Presenter: M. BollaPresenter's Affiliation: CHR de Grenoble, Grenoble, FranceType of Session: ScientificBackground A significant number of patients with clinical T1-2N0M0 prostate cancer are treated with radical prostatectmy. ... |
|
|
Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
This study discusses an off-label use of rituximab for the treatment of MCL. Presenter: W. HiddemannPresenter's Affiliation: Ludwig-Maximilians-University, Munchen, GermanyType of Session: ScientificBackground Mantle cell lymphoma (MCL) accounts for... |
|
|
Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): a prospective, multi-institutional trial
Presenter: D.F. HayesPresenter's Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MIType of Session: ScientificBackground The identification of markers that predict resistance to a treatment early in the course of therapy... |
|
|
MRI detection of multi focal breast carcinoma: Report from the International Breast MRI Consortium
Presenter: M. D. SchnallPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Single institution studies have suggested that MRI more accurately determines the extent of cancer within the breast compared... |
|
|
Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
This presentation discusses off-label use of bevacizumab for RCC. It also discusses the use of erlotinib for the treatment of RCC which has not been approved by the FDA. Presenter: J.D. HainsworthPresenter's Affiliation: Sarah Cannon Cancer... |
|
|
Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer
Presenter: M. YoshimotoPresenter's Affiliation: Cancer Institute Hospital, Tokyo, JapanType of Session: ScientificBackground Many breast cancer patients receive chemotherapy as part of their treatment program A common chemotherapeutic agent used... |
|
|
Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis
This study discusses an off-label use of rituximab for the treatment of NHL. Presenter: M. G. PfreundschuhPresenter's Affiliation: International Intergroup: Germany, Australia, Sweden, UK, Czech Republic, Canada, Poland, ItalyType of Session:... |
|
|
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)
This presentation discusses the off-label use of rituximab for the treatment of indolent NHL. Presenter: H.S. HochsterPresenter's Affiliation: ECOG/CALGBType of Session: ScientificBackground Indolent lymphomas (IL), as the name implies, have a... |
|
|
The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer
Presenter: P.L. NguyenPresenter's Affiliation: Harvard Medical School/ University of PennsylvaniaType of Session: ScientificBackground It has been demonstrated that prolonged delay between cancer diagnosis and the start of radiation therapy (RT) is... |
|
|
What we learned on June 5, 2004
The American Society of Clinical Oncology meeting was a wealth of information today. The take home message of what saw yesterday is discussed below and organized by disease type. Detailed coverage of the abstracts can be found on OncoLink for CME... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
